



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 46830

**Title:** The prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

**Reviewer's code:** 03733131

**Reviewer's country:** Japan

**Science editor:** Ying Dou

**Reviewer accepted review:** 2019-03-27 07:56

**Reviewer performed review:** 2019-03-31 11:03

**Review time:** 4 Days and 3 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

**Overview** This research article investigated the prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. However, there is a few 'anecdotal' information. This article is well written, organized, and within



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

the scope of the journal The minor issues 1. Lymphovascular invasion is an important prognostic factor in patients with malignant tumor (e. g. PMID: 29145818 and PMID: 30101131). Authors should evaluate the lymphovascular invasion of cases (exist or not exist is OK). 2. The manuscript would be better if authors refer to the presence or absence of background adenocarcinoma component in this study cases.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 46830

**Title:** The prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

**Reviewer’s code:** 00069601

**Reviewer’s country:** South Korea

**Science editor:** Ying Dou

**Reviewer accepted review:** 2019-03-27 07:50

**Reviewer performed review:** 2019-04-01 07:55

**Review time:** 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This manuscript analyzes the prognostic significance of 20 ng/dl, the new cut-off value of the castrate testosterone level on clinical outcome. Based on the results of this manuscript, the authors argue that 20 ng/dl better predicts biochemical failure free



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

survival (BFFS) compared to conventional 50 ng/dl. In order to make a more logical argument, the following points are considered to be necessary. 1. As the authors suggest, this manuscript was conducted in a single institution with relatively formal treatment protocol, but multivariate analysis involving other variables that might affect BFFS was not performed. If you have performed a multivariate cox regression analysis as described in materials and methods, it is essential to specify the parameters involved in the analysis and to mention the hazard ratio, confidential interval with the p value. 2. It is also necessary to mention the p value, sensitivity and specificity as well as AUC for each cutoff value in ROC analysis.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 46830

**Title:** The prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

**Reviewer's code:** 03677735

**Reviewer's country:** China

**Science editor:** Ying Dou

**Reviewer accepted review:** 2019-03-29 00:20

**Reviewer performed review:** 2019-04-07 02:36

**Review time:** 9 Days and 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This article is focused on the effect of two different castrate testosterone levels, <50 and <20 ng/dL, on biochemical relapse free survival (BRFS) in patients with non-metastatic intermediate and high risk PC receiving definitive RT and ADT. They have concluded



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

using castrate cut off value of 20 ng/dL is better in estimating the BRFS compared to 50 ng/dL. Minor revision 1. The unit of testosterone level is inconsistent: ng/dL, ng/mL. They should check the correct unit. 2. I would suggest to add “numbers at risks” into the figures. 3. In the paragraph 4 of DISCUSSION, I would suggest to add the P value of 10-year biochemical recurrence rates comparison.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No